Immune checkpoint inhibitors and elderly people: A review

European Journal of Cancer

Volumn 82, Issue , 2017, Pages 155-166

  Daste, Amaury ^a   Domblides, Charlotte ^a,b,c   Gross goupil, Marine ^a   Chakiba, Camille ^b,d   Quivy, Amandine ^a   Cochin, Valérie ^a,b   de Mones, Erwan ^e   Larmonier, Nicolas ^c   Soubeyran, Pierre ^b,d   Ravaud, Alain ^a,b,f  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNRS Bordeaux Segalen University   (France)

^d INSTITUT BERGONIÉ   (France)

^e HÔPITAL PELLEGRIN   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse events; Elderly people; Immune checkpoint inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR ANTIGEN;

AGED; AGING; ANTIGEN PRESENTING CELL; BLADDER CANCER; CANCER IMMUNOTHERAPY; CARCINOGENESIS; DRUG EFFICACY; DRUG SAFETY; GERIATRIC DISORDER; HEAD AND NECK CANCER; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOSENESCENCE; KIDNEY CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASM; MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; NEOPLASMS; PHYSIOLOGY; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

AGED; AGING; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85021700064     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.05.044     Document Type: Review

References (101)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer 66 (2016), 7–30.
2. Yancik, R., Ries, L.A.G., Cancer in older persons: an international issue in an ageing world. Semin Oncol 31 (2004), 128–136.
3. Talarico, L., Chen, G., Pazdur, R., Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22 (2004), 4626–4631.
4. Yee, K.W.L., Pater, J.L., Pho, L., Zee, B., Siu, L.L., Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol 21 (2003), 1618–1623.
5. Daste, A., Chakiba, C., Domblides, C., Gross-Goupil, M., Quivy, A., Ravaud, A., et al. Targeted therapy and elderly people: a review. Eur J Cancer 69 (2016), 199–215.
6. Linton, P.J., Dorshkind, K., Age-related changes in lymphocyte development and function. Nat Immunol 5 (2004), 133–139.
7. Grubeck-Loebenstein, B., Della Bella, S., Iorio, A.M., Michel, J.-P., Pawelec, G., Solana, R., Immunosenescence and vaccine failure in the elderly. Ageing Clin Exp Res 21 (2009), 201–209.
8. Valiathan, R., Ashman, M., Asthana, D., Effects of ageing on the immune system: infants to elderly. Scand J Immunol 83 (2016), 255–266.
9. Goronzy, J.J., Weyand, C.M., Immune ageing and autoimmunity. Cell Mol Life Sci 69 (2012), 1615–1623.
10. Hayflick, L., Moorhead, P.S., The serial cultivation of human diploid cell strains. Exp Cell Res 25 (1961), 585–621.
11. Pinti, M., Appay, V., Campisi, J., Frasca, D., Fülöp, T., Sauce, D., et al. Ageing of the immune system: focus on inflammation and vaccination. Eur J Immunol 46 (2016), 2286–2301.
12. Coppé, J.-P., Patil, C.K., Rodier, F., Sun, Y., Muñoz, D.P., Goldstein, J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumour suppressor. PLoS Biol 6 (2008), 2853–2868.
13. Franceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., et al. Inflammaging and anti-inflammaging: a systemic perspective on ageing and longevity emerged from studies in humans. Mech Ageing Dev 128 (2007), 92–105.
14. Fagiolo, U., Cossarizza, A., Scala, E., Fanales-Belasio, E., Ortolani, C., Cozzi, E., et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 23 (1993), 2375–2378.
15. Tu, W., Rao, S., Mechanisms underlying T cell immunosenescence: ageing and cytomegalovirus infection. Front Microbiol, 7, 2016, 2111.
16. Derhovanessian, E., Solana, R., Larbi, A., Pawelec, G., Immunity, ageing and cancer. Immun Ageing, 5, 2008, 11.
17. Rossi, D.J., Bryder, D., Zahn, J.M., Ahlenius, H., Sonu, R., Wagers, A.J., et al. Cell intrinsic alterations underlie hematopoietic stem cell ageing. Proc Natl Acad Sci USA 102 (2005), 9194–9199.
18. Berent-Maoz, B., Montecino-Rodriguez, E., Dorshkind, K., Genetic regulation of thymocyte progenitor ageing. Semin Immunol 24 (2012), 303–308.
19. Wang, J., Geiger, H., Rudolph, K.L., Immunoaging induced by hematopoietic stem cell ageing. Curr Opin Immunol 23 (2011), 532–536.
20. Pang, W.W., Price, E.A., Sahoo, D., Beerman, I., Maloney, W.J., Rossi, D.J., et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA 108 (2011), 20012–20017.
21. Lin, J., Zhu, Z., Xiao, H., Wakefield, M.R., Ding, V.A., Bai, Q., et al. The role of IL-7 in immunity and cancer. Anticancer Res 37 (2017), 963–967.
22. Rossi, D.J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., Weissman, I.L., Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447 (2007), 725–729.
23. Weiskopf, D., Weinberger, B., Grubeck-Loebenstein, B., The ageing of the immune system. Transplant Int 22 (2009), 1041–1050.
24. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
25. Fang, M., Roscoe, F., Sigal, L.J., Age-dependent susceptibility to a viral disease due to decreased natural killer cell numbers and trafficking. J Exp Med 207 (2010), 2369–2381.
26. Metcalf, T.U., Cubas, R.A., Ghneim, K., Cartwright, M.J., Grevenynghe, J.V., Richner, J.M., et al. Global analyses revealed age-related alterations in innate immune responses after stimulation of pathogen recognition receptors. Ageing Cell 14 (2015), 421–432.
27. Manser, A.R., Uhrberg, M., Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. Cancer Immunol Immunother 65 (2016), 417–426.
28. Cooper, M.A., Fehniger, T.A., Fuchs, A., Colonna, M., Caligiuri, M.A., NK cell and DC interactions. Trends Immunol 25 (2004), 47–52.
29. White, M.J., Nielsen, C.M., McGregor, R.H.C., Riley, E.H.C., Goodier, M.R., Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology 142 (2014), 140–150.
30. Hazeldine, J., Hampson, P., Lord, J.M., Reduced release and binding of perforin at the immunological synapse underlies the age-related decline in natural killer cell cytotoxicity. Ageing Cell 11 (2012), 751–759.
31. Hearps, A.C., Martin, G.E., Angelovich, T.A., Cheng, W.-J., Maisa, A., Landay, A.L., et al. Ageing is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Ageing Cell 11 (2012), 867–875.
32. Shaw, A.C., Goldstein, D.R., Montgomery, R.R., Age-dependent dysregulation of innate immunity. Nat Rev Immunol 13 (2013), 875–887.
33. Fülöp, T., Fóris, G., Wórum, I., Leövey, A., Age-dependent changes of the Fc gamma-receptor-mediated functions of human monocytes. Int Arch Allergy Appl Immunol 74 (1984), 76–79.
34. Nyugen, J., Agrawal, S., Gollapudi, S., Gupta, S., Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol 30 (2010), 806–813.
35. Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21 (2015), 938–945.
36. Plowden, J., Renshaw-Hoelscher, M., Gangappa, S., Engleman, C., Katz, J.M., Sambhara, S., Impaired antigen-induced CD8+ T cell clonal expansion in ageing is due to defects in antigen presenting cell function. Cell Immunol 229 (2004), 86–92.
37. Herrero, C., Marqués, L., Lloberas, J., Celada, A., IFN-γ–dependent transcription of MHC class II IA is impaired in macrophages from aged mice. J Clin Invest 107 (2001), 485–493.
38. Grolleau-Julius, A., Harning, E.K., Abernathy, L.M., Yung, R.L., Impaired dendritic cell function in ageing leads to defective antitumor immunity. Cancer Res 68 (2008), 6341–6349.
39. Goronzy, J.J., Fang, F., Cavanagh, M.M., Qi, Q., Weyand, C.M., Naive T cell maintenance and function in human ageing. J Immunol 194 (2015), 4073–4080.
40. Gruver, A.L., Hudson, L.L., Sempowski, G.D., Immunosenescence of ageing. J Pathol 211 (2007), 144–156.
41. Hirokawa, K., Utsuyama, M., Combined grafting of bone marrow and thymus, and sequential multiple thymus graftings in various strains of mice. The effect on immune functions and life span. Mech Ageing Dev 49 (1989), 49–60.
42. Yanes, R.E., Gustafson, C.E., Weyand, C.M., Goronzy, J.J., Lymphocyte generation and population homeostasis throughout life. Semin Hematol 54 (2017), 33–38.
43. Fagnoni, F.F., Vescovini, R., Passeri, G., Bologna, G., Pedrazzoni, M., Lavagetto, G., et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in ageing. Blood 95 (2000), 2860–2868.
44. Richner, J.M., Gmyrek, G.B., Govero, J., Tu, Y., van der Windt, G.J.W., Metcalf, T.U., et al. Age-dependent cell trafficking defects in draining lymph nodes impair adaptive immunity and control of west nile virus infection. PLoS Pathog, 11, 2015, e1005027.
45. Agrawal, A., Agrawal, S., Gupta, S., Dendritic cells in human ageing. Exp Gerontol 42 (2007), 421–426.
46. Li, G., Smithey, M.J., Rudd, B.D., Nikolich-Žugich, J., Age-associated alterations in CD8α+ dendritic cells impair CD8 T-cell expansion in response to an intracellular bacterium. Ageing Cell 11 (2012), 968–977.
47. Sridharan, A., Esposo, M., Kaushal, K., Tay, J., Osann, K., Agrawal, S., et al. Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age Dordr 33 (2011), 363–376.
48. Plowden, J., Renshaw-Hoelscher, M., Engleman, C., Katz, J., Sambhara, S., Innate immunity in ageing: impact on macrophage function. Ageing Cell 3 (2004), 161–167.
49. Dock, J.N., Effros, R.B., Role of CD8 T cell replicative senescence in human ageing and in HIV-mediated immunosenescence. Ageing Dis 2 (2011), 382–397.
50. Britanova, O.V., Putintseva, E.V., Shugay, M., Merzlyak, E.M., Turchaninova, M.A., Staroverov, D.B., et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol 192 (2014), 2689–2698.
51. Whisler, R.L., Chen, M., Liu, B., Newhouse, Y.G., Age-related impairments in TCR/CD3 activation of ZAP-70 are associated with reduced tyrosine phosphorylations of zeta-chains and p59fyn/p56lck in human T cells. Mech Ageing Dev 111 (1999), 49–66.
52. Pera, A., Campos, C., López, N., Hassouneh, F., Alonso, C., Tarazona, R., et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas 82 (2015), 50–55.
53. Fülöp, T., Larbi, A., Pawelec, G., Human T cell ageing and the impact of persistent viral infections. Front Immunol, 4, 2013, 271.
54. Vallejo, A.N., CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 205 (2005), 158–169.
55. Effros, R.B., Boucher, N., Porter, V., Zhu, X., Spaulding, C., Walford, R.L., et al. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 29 (1994), 601–609.
56. Pawelec, G., Hypothesis: loss of telomerase inducibility and subsequent replicative senescence in cultured human T cells is a result of altered costimulation. Mech Ageing Dev 121 (2000), 181–185.
57. Koch, S., Larbi, A., Derhovanessian, E., Ozcelik, D., Naumova, E., Pawelec, G., Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing, 5, 2008, 6.
58. Papagno, L., Spina, C.A., Marchant, A., Salio, M., Rufer, N., Little, S., et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol, 2, 2004, E20.
59. Ruby, C.E., Weinberg, A.D., OX40-enhanced tumour rejection and effector T cell differentiation decreases with age. J Immunol 182 (2009), 1481–1489.
60. Molon, B., Calì, B., Viola, A., T cells and cancer: how metabolism shapes immunity. Front Immunol, 7, 2016, 20.
61. Thoman, M.L., Weigle, W.O., Lymphokines and ageing: interleukin-2 production and activity in aged animals. J Immunol 127 (1981), 2102–2106.
62. Wikby, A., Johansson, B., Olsson, J., Löfgren, S., Nilsson, B.O., Ferguson, F., Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 37 (2002), 445–453.
63. Wikby, A., Maxson, P., Olsson, J., Johansson, B., Ferguson, F.G., Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non-survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev 102 (1998), 187–198.
64. Farber, D.L., Yudanin, N.A., Restifo, N.P., Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 14 (2014), 24–35.
65. Po, J.L.Z., Gardner, E.M., Anaraki, F., Katsikis, P.D., Murasko, D.M., Age-associated decrease in virus-specific CD8+ T lymphocytes during primary influenza infection. Mech Ageing Dev 123 (2002), 1167–1181.
66. Elias, R., Karantanos, T., Sira, E., Hartshorn, K.L., Immunotherapy comes of age: immune ageing & checkpoint inhibitors. J Geriatr Oncol 8 (2017), 229–235.
67. Verschoor, C.P., Johnstone, J., Millar, J., Dorrington, M.G., Habibagahi, M., Lelic, A., et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 93 (2013), 633–637.
68. Pawelec, G., Immunosenescence and cancer. Biogerontology, 2017, 10.1007/s10522-017-9682-z [Epub ahead of print].
69. Grizzle, W.E., Xu, X., Zhang, S., Stockard, C.R., Liu, C., Yu, S., et al. Age-related increase of tumour susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev 128 (2007), 672–680.
70. Xiang, X., Poliakov, A., Liu, C., Liu, Y., Deng, Z., Wang, J., et al. Induction of myeloid-derived suppressor cells by tumour exosomes. Int J Cancer 124 (2009), 2621–2633.
71. Tsukamoto, H., Senju, S., Matsumura, K., Swain, S.L., Nishimura, Y., IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun, 6, 2015, 6702.
72. Lages, C.S., Suffia, I., Velilla, P.A., Huang, B., Warshaw, G., Hildeman, D.A., et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 181 (2008), 1835–1848.
73. Foster, A.D., Sivarapatna, A., Gress, R.E., The ageing immune system and its relationship with cancer. Ageing Health 7 (2011), 707–718.
74. Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17 (2016), 956–965.
75. Chow, L.Q.M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:32 (2016), 3838–3845, 10.1200/JCO.2016.68.1478.
76. Ferris, R.L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
77. McDermott, D.F., Sosman, J.A., Sznol, M., Massard, C., Gordon, M.S., Hamid, O., et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34 (2016), 833–842.
78. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
79. Plimack, E.R., Bellmunt, J., Gupta, S., Berger, R., Chow, L.Q.M., Juco, J., et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18 (2017), 212–220.
80. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
81. Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
82. Balar, A.V., Galsky, M.D., Rosenberg, J.E., Powles, T., Petrylak, D.P., Bellmunt, J., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
83. Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.-L., Fong, L., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
84. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
85. Chiarion Sileni, V., Pigozzo, J., Ascierto, P.A., Grimaldi, A.M., Maio, M., Di Guardo, L., et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res, 33, 2014, 30.
86. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
87. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
88. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
89. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
90. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
91. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
92. Friedman, C.F., Claire Frances, T.Z., Minehart, J., Panageas, K., Callahan, M.K., Chapman, P.B., et al. Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+). J Clin Oncol, 34, 2016 (suppl; abstr 10009).
93. Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
94. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
95. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl 389 (2017), 255–265.
96. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
97. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
98. Grossi, F., Crinò, L., Bidoli, P., Delmonte, A., Gelsomino, F., Proto, C., et al. Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy. Ann Oncol, 27(Suppl. 6), 2016 1079P.
99. Antonia, S., Goldberg, S.B., Balmanoukian, A., Chaft, J.E., Sanborn, R.E., Gupta, A., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17 (2016), 299–308.
100. Friedman, C.F., Proverbs-Singh, T.A., Postow, M.A., Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2 (2016), 1346–1353.
101. Singh, H., Kim, G., Maher, V.E., Beaver, J.A., Pai-Scherf, L.H., Balasubramaniam, S., et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol, 34, 2016 (suppl; abstr 10010).